… a while, whilst MAO‐B inhibitors and dopamine agonists may … B inhibitors with other types
of medication in people with early Parkinson's to see if there was good evidence that MAO‐B …

… Thus, trials comparing MAO‐B inhibitor and levodopa versus levodopa, or MAO‐B
inhibitor and a dopamine agonist versus a dopamine agonist, were included. Trials in which …

… BR COUNSELL … We gratefully acknowledge help from Mrs B. Pelling and Miss Margaret
Meek in retrieving notes and to the Department of Medical Photography for illustrations. …

Background Gout is an increasingly prevalent form of inflammatory arthritis. Although
effective treatments for gout exist, current management is suboptimal due to low medication …

Objective To quantify more reliably the benefits and risks of monoamine oxidase type B
inhibitors (MAOBIs) in early Parkinson's disease. Data sources Searches of the Cochrane Library…

Purpose The treatment of patients with diffuse large B-cell lymphoma (DLBCL) with cardiac
comorbidity is problematic, because this group may not be able to receive anthracycline-…

Importance Many people with Parkinson disease (PD) develop motor complications that are
uncontrolled by levodopa dose adjustment. Among these patients, it is uncertain which drug …

Background Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL)
is associated with a dismal prognosis. Here, we report an analysis of CNS relapse for …

Background There is an on-going debate whether 2- or 3-weekly administration of R-CHOP
is the preferred first-line treatment for elderly patients with diffuse large B-cell lymphoma (…

PRD-92 a well-absorbed mast cell stabilizer was examined in patients with ulcerative colitis
by a double-blind controlled trial. Forty-three patients who were in clinical remission or PRD-…